The present invention relates to modified or polymer conjugated MetAP2 inhibitors for use in improving or restoring insulin sensitivity in a subject in need thereof, wherein the subject is overweight or obese. Also disclosed is the modified or polymer conjugated MetAP2 inhibitors for use in methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome or in methods of improving glycemic control, reducing insulin levels and/or improving leptin sensitivity.
